Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EOLS Evolus	$9.20 -1.5%	$9.59	$8.67 ▼ $17.82	$593.22M	0.97	769,980 shs	879,666 shs
KALV KalVista Pharmaceuticals	$15.39 -3.9%	$12.82	$7.30 ▼ $16.32	$768.73M	-0.04	587,610 shs	1.28 million shs
MOLN Molecular Partners	$3.63 -0.7%	$3.78	$3.36 ▼ $12.22	$146.38M	1.1	14,433 shs	408 shs
URGN Urogen Pharma	$15.27 -0.9%	$10.28	$3.42 ▼ $17.00	$705.47M	1.02	1.10 million shs	1.20 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EOLS Evolus	+1.52%	-4.01%	+0.97%	-13.44%	-21.84%
KALV KalVista Pharmaceuticals	+1.39%	+3.22%	+31.77%	+33.42%	+6.95%
MOLN Molecular Partners	+1.11%	+0.94%	-3.23%	-7.83%	-43.88%
URGN Urogen Pharma	+7.46%	+5.26%	+16.39%	+59.36%	-8.76%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EOLS Evolus	3.9554 of 5 stars	3.5	0.0	3.5	2.9	3.3	0.6
KALV KalVista Pharmaceuticals	4.076 of 5 stars	3.6	1.0	4.4	3.2	1.7	0.6
MOLN Molecular Partners	3.1256 of 5 stars	3.8	5.0	0.0	2.7	0.0	0.6
URGN Urogen Pharma	4.3382 of 5 stars	4.5	2.0	4.5	1.3	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EOLS Evolus	3.00	Buy	$23.75	158.15% Upside
KALV KalVista Pharmaceuticals	3.11	Buy	$26.29	70.80% Upside
MOLN Molecular Partners	3.50	Strong Buy	$12.00	231.03% Upside
URGN Urogen Pharma	3.00	Buy	$32.86	115.17% Upside

Current Analyst Ratings Breakdown

Latest MOLN, URGN, KALV, and EOLS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/8/2025	KALV KalVista Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$19.00 ➝ $27.00
7/8/2025	KALV KalVista Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $27.00
7/8/2025	URGN Urogen Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00
7/7/2025	KALV KalVista Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$18.00 ➝ $20.00
7/7/2025	URGN Urogen Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
6/16/2025	URGN Urogen Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$50.00
6/13/2025	URGN Urogen Pharma	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Neutral ➝ Neutral	$16.00
6/13/2025	URGN Urogen Pharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Buy	$31.00
6/13/2025	URGN Urogen Pharma	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
6/13/2025	URGN Urogen Pharma	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$23.00 ➝ $47.00
6/13/2025	URGN Urogen Pharma	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $30.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EOLS Evolus	$266.27M	2.23	N/A	N/A	$0.09 per share	102.22
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	$1.92 per share	N/A
MOLN Molecular Partners	$5.65M	25.91	N/A	N/A	$3.99 per share	0.91
URGN Urogen Pharma	$90.40M	7.80	N/A	N/A	($0.21) per share	-72.71

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EOLS Evolus	-$50.42M	-$0.89	N/A	N/A	N/A	-20.40%	-759.04%	-20.14%	7/30/2025 (Estimated)
KALV KalVista Pharmaceuticals	-$183.44M	-$3.69	N/A	N/A	N/A	N/A	-134.07%	-82.65%	9/4/2025 (Estimated)
MOLN Molecular Partners	-$61.39M	-$1.92	N/A	N/A	N/A	N/A	-42.20%	-38.12%	8/25/2025 (Estimated)
URGN Urogen Pharma	-$126.87M	-$3.18	N/A	N/A	N/A	-150.68%	-97,487.15%	-49.57%	8/12/2025 (Estimated)

Latest MOLN, URGN, KALV, and EOLS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	URGN Urogen Pharma	-$0.85	N/A	N/A	N/A	$23.06 million	N/A
7/30/2025	Q2 2025	EOLS Evolus	-$0.09	N/A	N/A	N/A	$82.18 million	N/A
7/10/2025	Q4 2025	KALV KalVista Pharmaceuticals	-$0.83	-$3.69	-$2.86	-$0.99	$4.20 million	N/A
5/15/2025	Q1 2025	MOLN Molecular Partners	-$0.3855	-$0.50	-$0.1145	-$0.50	N/A	N/A
5/12/2025	Q1 2025	URGN Urogen Pharma	-$0.83	-$0.92	-$0.09	-$0.92	$22.71 million	$20.25 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EOLS Evolus	N/A	N/A	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MOLN Molecular Partners	N/A	N/A	N/A	N/A	N/A
URGN Urogen Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EOLS Evolus	22.00	2.34	2.16
KALV KalVista Pharmaceuticals	N/A	5.35	5.35
MOLN Molecular Partners	N/A	15.28	15.28
URGN Urogen Pharma	N/A	5.65	5.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EOLS Evolus	90.69%
KALV KalVista Pharmaceuticals	N/A
MOLN Molecular Partners	26.55%
URGN Urogen Pharma	91.29%

Insider Ownership

Company	Insider Ownership
EOLS Evolus	5.90%
KALV KalVista Pharmaceuticals	10.50%
MOLN Molecular Partners	5.93%
URGN Urogen Pharma	5.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EOLS Evolus	170	64.48 million	60.67 million	Optionable
KALV KalVista Pharmaceuticals	100	49.95 million	44.71 million	Optionable
MOLN Molecular Partners	180	40.38 million	37.98 million	Not Optionable
URGN Urogen Pharma	200	46.20 million	43.76 million	Optionable

MOLN, URGN, KALV, and EOLS Headlines

Recent News About These Companies

Migdal Insurance & Financial Holdings Ltd. Increases Stake in Urogen Pharma (NASDAQ:URGN)

July 18 at 10:01 AM | marketbeat.com

URGN Class Action News: UroGen Pharma Ltd. Investors with Large Losses Should Contact Robbins LLP Before July 28 for Information About Leading the Class Action

July 17 at 4:29 PM | globenewswire.com

UROGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Class Action Lawsuit ...

July 16 at 4:21 AM | reflector.comR

UROGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Class Action Lawsuit Against UroGen Pharma Ltd.

July 15 at 8:32 PM | globenewswire.com

Lowey Dannenberg Notifies UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDQ: URGN) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm

July 11, 2025 | globenewswire.com

UroGen Pharma Shows Market Leadership With Jump To 81 RS Rating

July 11, 2025 | msn.com

Urogen Pharma's (URGN) Buy Rating Reiterated at HC Wainwright

July 11, 2025 | americanbankingnews.com

Urogen Pharma (NASDAQ:URGN) Receives "Buy" Rating from HC Wainwright

July 8, 2025 | marketbeat.com

UroGen Pharma’s Promising Outlook: Buy Rating Backed by Clinical Success and FDA Approvals

July 8, 2025 | tipranks.com

Urogen Pharma (NASDAQ:URGN) Given Buy Rating at D. Boral Capital

July 8, 2025 | americanbankingnews.com

Urogen Pharma (NASDAQ:URGN) Earns Buy Rating from D. Boral Capital

July 7, 2025 | marketbeat.com

UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

July 7, 2025 | globenewswire.com

UroGen Pharma Receives FDA Approval for ZUSDURI for Recurrent Bladder Cancer

July 6, 2025 | msn.com

Harel Insurance Investments & Financial Services Ltd. Cuts Position in Urogen Pharma (NASDAQ:URGN)

July 4, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - URGN

July 2, 2025 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - URGN

July 1, 2025 | globenewswire.com

URGN Stock News: Robbins LLP Reminds UroGen Pharma Ltd. Investors of the Pending Lead Plaintiff Deadline in the URGN Class Action – Contact Robbins LLP Before July 28 for Information

June 30, 2025 | globenewswire.com

URGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

June 30, 2025 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN

June 27, 2025 | prnewswire.com

Urogen Pharma (NASDAQ:URGN) Trading Down 5.3% - Time to Sell?

June 24, 2025 | marketbeat.com

Urogen Pharma (NASDAQ:URGN) Given Average Recommendation of "Buy" by Brokerages

June 24, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MOLN, URGN, KALV, and EOLS Company Descriptions

Evolus NASDAQ:EOLS

$9.20 -0.14 (-1.50%)

Closing price 04:00 PM Eastern

Extended Trading

$9.21 +0.01 (+0.11%)

As of 04:26 PM Eastern

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

KalVista Pharmaceuticals NASDAQ:KALV

$15.39 -0.62 (-3.87%)

Closing price 04:00 PM Eastern

Extended Trading

$15.38 -0.01 (-0.03%)

As of 04:27 PM Eastern

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.

Molecular Partners NASDAQ:MOLN

$3.62 -0.03 (-0.68%)

Closing price 03:27 PM Eastern

Extended Trading

$3.62 0.00 (0.00%)

As of 04:04 PM Eastern

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Urogen Pharma NASDAQ:URGN

$15.27 -0.14 (-0.91%)

Closing price 04:00 PM Eastern

Extended Trading

$15.22 -0.05 (-0.33%)

As of 04:16 PM Eastern

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time